Hypothalamic Control of Lipid Metabolism: Focus on Leptin, Ghrelin and Melanocortins

Carlos Diéguez, María J. Vazquez, Amparo Romero, Miguel López, Ruben Nogueiras

Introduction

The central nervous system (CNS) modulates energy balance by regulating food intake and energy expenditure in response to hormones as well as neuronal or nutrient signals. Although several regions of the CNS participate in these actions, the most frequently studied is perhaps the hypothalamus. The hypothalamus is constituted in anatomically defined neuronal clusters, called nuclei, forming interconnected neuronal circuits via axonal projections. Hypothalamic nuclei are sensitive to nutrients and hormones and modify the expression, secretion and activity of specific neurotransmitters and neuromodulators, resulting in changes in energy intake and energy expenditure [1]. In mammals, neurons, particularly in the arcuate nucleus of the hypothalamus (ARC), are involved in the regulation of energy homeostasis [2]. One regulatory pathway consists of neurons co-expressing neuropeptide Y (NPY) and agouti-related protein (AgRP), both potent stimulators of food intake [3]. These cells...
Hypothalamic Lipid Metabolism Modulates Energy Homeostasis

There are numerous reports demonstrating that hypothalamic lipid metabolism is a crucial mechanism regulating energy homeostasis. Anatomical data show that key enzymes modulating lipid metabolism, such as AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), carnitine palmitoyltransferase I (CPT1), fatty acid synthase (FAS) and malonyl-CoA decarboxylase, are found in high levels in hypothalamic nuclei including ARC, dorsomedial, paraventricular (PVH) and ventromedial (VMH) nuclei, which are closely related with the regulation of food intake and energy expenditure [12]. Treatments with FAS inhibitors, such as cerulenin and C75, or drugs that decrease FAS expression, like tamoxifen, cause suppression of food intake and the loss of body weight [13–15]. The anorectic effect of these drugs requires the accumulation of malonyl-CoA in the hypothalamus, which may be sensed as a signal of nutrient abundance by critical neurons regulating food intake (‘malonyl-CoA hypothesis’) [13] and decreased expression of orexigenic (AgRP and NPY) and elevated expression of anorexigenic (CART, POMC) neuropeptides in the ARC [13]. Hypothalamic malonyl-CoA is also modulated by nutritional status. Fasting reduces the production of hypothalamic malonyl-CoA [13, 15, 16], reprogramming metabolic substrate utilization away from glycolysis and toward lipid oxidation [17].

There are two potential theories that may explain the molecular pathways mediating the actions of FAS inhibitors. The first theory suggests that malonyl-CoA or a derivative interacts directly with a signaling protein that regulates expression of neuropeptides. This is the case in mice lacking FAS in the hypothalamus, which are leaner and hypophagic [18]. They also present with increased hypothalamic levels of malonyl-CoA and impaired expression of ARC-derived neuropeptides [18]. Similar findings were obtained after genetic disruption of hypothalamic AMPK by using adenoviruses, which decrease food intake [16, 19]. The second theory suggests that malonyl-CoA acts indirectly on CPT1, and thus prevents the access of long-chain fatty acyl-CoA to the mitochondria, which would decrease food intake. This theory is demonstrated by the fact that pharmacological inhibition or genetic ablation of hypothalamic CPT1 activity inhibits feeding [20–22], indicating that the accumulation of fatty acyl-CoA is the mediator in the signaling pathway modulating feeding.

Physiological findings have also shown that regulation of hypothalamic fatty acid metabolism is part of the adaptive changes observed during physiological regulation of feeding. Fasting stimulates hypothalamic AMPK and inhibits ACC and FAS activities, whereas re-feeding induces opposite changes [15, 16, 19, 23]. Furthermore, hypothalamic AMPK and consequently, ACC and FAS activities, are modulated by peripheral signals that are crucial for the regulation of energy balance. Anorectic hormones, such as leptin, insulin, glucagon-like peptide-1, ciliary neurotrophic factor and melanocortin receptors agonists (e.g. melanotan II), inhibit hypothalamic AMPK and activate ACC and/or FAS [12]. On the other hand, orexigenic signals, such as cannabinoids, glucocorticoids, adiponectin, ghrelin and AgRP, activate AMPK and inhibit ACC and FAS [12]. Of note, rather than feeding, thyroid hormones control brown adipose tissue thermogenesis through specific action on AMPK in the VMH [24]. In addition to hormonal signals and neuropeptides, hypothalamic AMPK and ACC are also modulated by nutrients and intermediate metabolites, including glucose [19, 25, 26], α-lipoic acid [27], citrate [28] and lactate [29].

Finally, it is important to mention that hypothalamic fatty acids not only play an important role within the CNS, but peripheral fatty acids also exert a key signaling role on hypothalamic neurons. Most importantly, the impairment of this process could be involved in obesity development and/or maintenance [30].
CNS Leptin and Hypothalamic Lipid Metabolism

Leptin is a satiety hormone, secreted by, and in proportion to adipose tissue, informing the hypothalamus of the status of energy stores [31, 32]. One of the factors required by leptin to exert its anorectic effect is hypothalamic AMPK (fig. 1). This was demonstrated by injecting leptin into fasted mice expressing the dominant negative or constitutively active AMPK in the medial hypothalamus. Leptin decreased body weight and food intake in control mice and mice expressing dominant negative AMPK, but failed to do so in mice expressing constitutively active AMPK [19]. This indicates that suppression of AMPK activity in the medial hypothalamus is necessary for leptin’s anorexic and weight loss effects and that lack of suppression causes leptin resistance [19]. The inhibition of AMPK caused by central injection of leptin activates ACC in the ARC and the PVH of the hypothalamus [23]. Consistently, the overexpression of constitutively active AMPK in the ARC blunts the activation of ACC in the ARC in response to central leptin, reinforcing the hypothesis that AMPK is upstream of ACC in the leptin receptor-mediated intracellular signaling pathway [23]. Accordingly, the inhibition of hypothalamic ACC blocks the actions of leptin on feeding behavior, body weight and NPY mRNA expression [23]. Overall, these results show that hypothalamic ACC is an essential modulator of leptin’s effects. Furthermore, intracerebroventricular leptin increases malonyl-CoA levels specifically in the ARC and increases the level of palmitoyl-CoA specifically in the PVH [23]. Although the role of fatty acids as mediators of the actions of leptin is well documented, the precise molecular events occurring after the changes in malonyl-CoA and before NPY activation are still unknown and deserve further attention (fig. 1).

CNS Leptin Action and Peripheral Lipid Metabolism

Leptin is an adipocyte-derived satiety hormone whose effects are mediated by neuronal pathways. The leptin receptor is expressed in several brain areas that mediate the central actions of leptin. Leptin induces opposite effects on two ARC neuronal subpopulations: it directly inhibits the orexigenic NPY/AgRP-containing neurons and it stimulates the electrical activity of anorexigenic POMC neurons [4] (fig. 2). After the discovery of its anorectic role, it was demonstrated that leptin also regulated peripheral lipid and glucose metabolism [33–35]. In vivo studies revealed that leptin treatment stimulated lipolytic action in adipose tissues [36]. Later reports showed that central leptin infusion into the mediobasal hypothalamus of rats inhibited the synthesis of lipids in WAT [37]. For instance, 4-day central infusion of leptin decreased the expression of stearoyl-CoA-desaturase-1 (fig. 2), the rate-limiting enzyme during de novo conversion of saturated fatty acids to the monounsaturated fatty acids in WAT [38]. Similar data were obtained after 1 week of treatment [39]. Another study showed that the administration of leptin into the third cerebral ventricle increased the gene expression of hormone-sensitive lipase, a marker of lipolysis, in WAT [40] (fig. 2). Overall, it can be concluded that leptin, acting at the central level, decreases fat tissue mass and lipid accumulation. The lipolytic actions of CNS leptin on adipocyte metabolism require intact autonomic innervation because sympathetic denervation of adipose tissue abolished leptin’s effects [37]. The signal transduction pathway mediating the lipolytic action of central leptin is phosphoinositide 3-kinase, but not the signal transducer and activator of transcription 3 [37] (fig. 2). This was demonstrated by the administration of specific antagonists for both transcription factors, and

Fig. 1. CNS leptin modulates hypothalamic fatty acid metabolism, leading to stimulation or suppression of food intake respectively. The hypothalamic AMPK-fatty acid pathway seems to be essential for both hormones, and changes in malonyl-CoA and palmitoyl-CoA precede the inhibition of NPY. The red square and red arrow indicate the hypothetical molecular steps which have not been described. OB-R = Leptin receptor.
the results indicated that only inhibitors of phosphoinosi- 
tide 3-kinase blocked the central action of leptin, whereas 
the blockade of the signal transducer and activator of 
transcription 3 did not modify the lipolytic effects of 
leptin [37]. However, it is important to point out that one 
study suggests that leptin regulates peripheral lipid me-
tabolism through its anorexigenic action [41]. Although 
definitive proof is lacking, it is possible that the loss of 
adipose tissue in treated patients with mutations of the 
leptin-gene could be mediated by leptin’s effects on food 
intake as well as by its lipolytic action exerted at the cen-
tral level.

Indeed, all the studies concerning the actions of leptin 
on fatty acid metabolism have been done using rodents 
fed on standard diet. It is well known that the develop-
ment of obesity and leptin resistance in rodents on high-
fat diets is divided into three steps. In the initial stage, the 
mice gain fat but leptin is still effective in decreasing food 
intake. In the middle stage, rodents lose peripheral leptin 
 sensitivity while central leptin is still active. In the latter 
stage, mice also develop central leptin resistance [42]. 
There are two hypotheses to explain this leptin resis-
tance. One refers to the failure of circulating leptin to 
reach the CNS [43] and the other suggests that there is a 
failure in the leptin receptor signaling pathway [44]. Al-
though the effects of leptin on fatty acid metabolism have 
not been studied according to the stages of leptin resis-
tance, it is reasonable to hypothesize that its lipolytic ac-
tions would work similarly to its anorectic effect.

### CNS Ghrelin and Hypothalamic Lipid Metabolism

Ghrelin is a hormone produced in the stomach that 
increases food intake [6, 45]. Since its discovery in 1999, 
it has been studied as a potential anti-obesity therapeutic 
target because central and peripheral ghrelin administra-
tion induces weight gain and adiposity in rodents [45]. In 
humans, ghrelin also stimulates voluntary food intake 
[46]. Regarding its regulation, circulating ghrelin levels 
are decreased in human and rodent obesity [47] and are 
elevated in patients with anorexia nervosa or animals af-
ter fasting or in states of cachexia [48]. Moreover, subjects 
with a low BMI have higher ghrelin levels than lean sub-

---

**Fig. 2.** CNS leptin decreases peripheral lipid deposition. Leptin 
requires phosphoinositide 3-kinase (PI3K) to modulate adipocyte 
metabolism, and hypothalamic neuropeptides (NPY/AgRP vs. 
POMC/CART), and thereby melanocortin receptors, are likely to 
be involved in the lipolytic action of leptin. Red arrows indicate 
the hypothetical molecular steps which have not been described 
for the lipolytic action of leptin. OB-R = Leptin receptor; SNS = 
sympathetic nervous system; SCD1 = stearoyl-CoA-desaturase-1; 
HSL = hormone-sensitive lipase.
Hypothalamic Control of Lipid Metabolism

Patients with Prader-Willi syndrome, characterized by several disorders including hyperphagia and obesity which have high ghrelin levels, are exceptions to this regulation [49]. Studies with preclinical models using ghrelin knockout (KO) mice [50] or ghrelin receptor KO [growth hormone secretagogue receptor (GHS-R) KO] mice [51] have shown that the loss of ghrelin function protects against early-onset diet-induced obesity.

During post-translational modification of the ghrelin precursor protein, serine-3 is acylated with an eight-carbon fatty acid (octanoate). Octanoylation of ghrelin is a specific modification that is required for ghrelin to bind to its receptor GHS-R1a and to exert most of its biological properties. Although ghrelin in its unacylated form is believed to be the dominant form of ghrelin in the plasma, most of the biological actions ascribed to ghrelin needs acylation [52], including growth hormone secretion, feeding, insulin secretion and adiposity. The enzyme responsible for the octanoylation of ghrelin is ghrelin O-acyltransferase [53, 54], which is also called membrane-bound O-acyltransferase 4.

In regard to its biological actions, ghrelin increases food intake through GHS-R1a (fig. 3), as demonstrated in mice deficient in GHS-R1a, which do not respond to exogenously administered ghrelin in terms of food intake [55]. GHS-R1a is expressed in NPY/AgRP neurons in the hypothalamic ARC [56, 57], indicating that this set of neurons is involved in ghrelin action. Along these lines, adult male rats (fed or fasted) treated centrally (intracerebroventricular) with ghrelin showed increased AgRP and NPY electrical activity and expression in the ARC [6, 58] (fig. 3). Contrarily, ghrelin inhibits the activity of POMC neurons by increasing the inhibitory tone onto them [58]. The physiological relevance of both neuropeptides as mediators of ghrelin effects was firmly established by assessing the response to ghrelin in KO mice. These elegant experiments indicated that while NPY KO or AgRP KO showed a normal response in terms of food intake to ghrelin, the double KO NPY/AgRP failed to show any response, evidencing the existence of redundancy among these two neuropeptides as mediators of ghrelin orexigenic action [59].

Fig. 3. CNS ghrelin activates sirtuin 1 (SIRT1) and AMPK, thereby modulating hypothalamic fatty acid metabolism and leading to stimulation of transcription factors essential for NPY/AgRP, which ultimately affects food intake. The red arrow indicates the hypothetical molecular step which has not been described. The question mark indicates a black box in the molecular events triggered after the activation of the GHS-R1 and before sirtuin 1. UCP2 = Uncoupling protein 2; pCREB = phosphorylated cAMP response-element binding protein; FoxO1 = forkhead box O1.
Although it was clear that NPY/AgRP were necessary for the actions of ghrelin, it was unknown which specific molecular pathways regulated the expression of these neuropeptides. It has been recently reported that the hypothalamic homeobox domain transcription factor Bsx interacts with the two other transcription factors to activate AgRP and NPY mRNA expression: the forkhead box O1 and the phosphorylated cAMP response-element binding protein, respectively [60, 61]. Thus, Bsx, together with forkhead box O1 and phosphorylated cAMP response-element binding protein, plays an essential role in the CNS controlling the hyperphagic responses elicited by ghrelin in both male and female rats [60, 62].

Recently, it was also reported that hypothalamic fatty acid metabolism mediates the orexigenic effect of ghrelin [16, 63, 64]. Combining pharmacological and genetic techniques, it was demonstrated that the ghrelin-induced food intake activates hypothalamic sirtuin 1, which deacetylates p53 and thereby activates AMPK [65] (fig. 3). The activation of AMPK subsequently inhibits the synthesis of fatty acids, leading to lower hypothalamic levels of malonyl-CoA and increased CPT1 activity [16] (fig. 3). The hypothalamic fatty acid oxidation pathway modulated by AMPK, together with the decrease of FAS expression in the VMH and the activation of CPT1, leads to changes in hypothalamic mitochondrial respiration and production of reactive oxygen species in mice, which are dependent on uncoupling protein 2 [64]. This activation of the mitochondrial mechanism is essential for ghrelin-induced mitochondrial proliferation and the activation of NPY/AgRP neurons, ghrelin-triggered synaptic plasticity of POMC neurons, and ghrelin-induced food intake [64] (fig. 3).

CNS Ghrelin and Peripheral Lipid Metabolism

As mentioned above, one of the most significant actions of ghrelin is to stimulate the development of adiposity [45]. The mechanisms mediating the actions of ghrelin on adipose tissue seem to involve the autonomic nervous system. A single injection of ghrelin in the third cerebral

---

Fig. 4. CNS ghrelin favors peripheral lipid deposition and therefore increases adiposity. The central melanocortin system is one of the most important targets for both hormones and is very likely key for ghrelin and leptin direct actions on adipocyte metabolism. Ghrelin binds to its receptor and hypothalamic neuropeptides (NPY/AgRP vs. POMC), and thereby melanocortin receptors are likely involved in the lipogenic action of ghrelin. Red arrows indicate the hypothetical molecular steps which have not been described for the lipogenic action of ghrelin. SCD1 = Stearoyl-CoA-desaturase-1.
ventricle decreases sympathetic nervous activity in brown adipose tissue [52]. On the other hand, chronic central ghrelin infusion increases lipogenic enzyme expression in WAT including FAS, stearoyl-CoA-desaturase-1, ACCα and LPL, whereas it decreases the expression of the fat-oxidation promoting CPT1 in the WAT of rats (fig. 4). Interestingly, these central effects of ghrelin on adipocyte metabolism were tissue-specific and independent of food intake [66]. The molecular pathway linking central ghrelin with adipocytes is the sympathetic nervous system (fig. 4), as demonstrated by the fact that in mice lacking the three main types of β-adrenoceptors (β1, β2 and β3), which play a key role in the control of lipolysis, ghrelin failed to modify body weight and did not alter the expression of enzymes regulating lipid synthesis or degradation [66]. Importantly, these effects of central ghrelin on peripheral lipid metabolism are growth hormone-independent [67]. This was demonstrated using a model for the study of growth hormone deficiency. These dwarf rats were centrally treated with ghrelin and showed an increase in body fat [67]. Central ghrelin regulated hepatic lipogenesis de novo in a growth hormone-independent fashion; however, it regulated lipid mobilization in a growth hormone-dependent fashion because CPT1 was decreased only in control rats but not in growth hormone-deficient rats [67]. Concurring with these results was another study that found that chronic treatment with intravenous ghrelin also increased adiposity in rats and these effects were dependent on the GHS-R [68]. Contrarily, a report investigating the acute effects of ghrelin in humans found that lipolysis was increased independently of growth hormone signaling [69].

Another important action of CNS ghrelin is the regulation of cholesterol levels. Daily subcutaneous administration of ghrelin in wild-type mice for 1 week significantly increased total plasma cholesterol levels. Accordingly, the endogenous ghrelin system also has a physiological role in the regulation of cholesterol, as mice lacking ghrelin and ghrelin receptors had reduced circulating cholesterol [70].

**CNS Melanocortins and Peripheral Lipid Metabolism**

The melanocortins are a family of peptides produced from the post-translational processing of POMC. This family of neuropeptides possesses a unique feature: they have an endogenous agonist (α-melanocyte-stimulating hormone) and antagonist (AgRP), both of which share common melanocortin receptors. POMC and AgRP ne-

rons are situated in different neuronal populations of the ARC that function in parallel [71]. Melanocortins act through a family of five members of G-protein-coupled receptors (MCRs) [71]. The most relevant receptors in terms of energy balance regulation are MC3R and MC4R. Receptor agonist delivery into the hypothalamus reduces food intake, body weight and fat mass [3], whereas the administration of receptor antagonists (or inverse agonists) triggers opposite effects [3]. The relevance of the endogenous function of the melanocortin system has been investigated using genetically manipulated mice. Importantly, the phenotypes resulting from mutations in the genes Pomc or Mcr in rodents can be translated to humans. Moreover, mutations in the Mc4r gene are the most common monogenic cause of severe obesity in humans [72].

Recent evidence suggests that the CNS melanocortin system may directly regulate fat metabolism (fig. 2, 4). Anatomical studies have demonstrated that central WAT sympathetic outflow neurons express MC4R [73]. Moreover, the administration of MC3/4R agonists in the CNS decreased body fat in rodents by stimulating lipolysis independent of food intake [74]. Central melanocortins modulate the norepinephrine turnover, which is the principal initiator of lipolysis in mammals. Norepinephrine is released from the sympathetic nerves innervating WAT, and the central injection of a MC3/4R agonist increased the norepinephrine turnover in specific fat depots [75]. The mechanism mediating the action of melanocortins on norepinephrine is mediated by perilipin A and hormone-sensitive lipase, which are essential for norepinephrine-triggered lipolysis [76]. Consistent with this data, treatment with MC3R and MC4R antagonists increased stearoyl-CoA-desaturase-1 expression in WAT [38]. Therefore, blockade of the CNS melanocortin system increased lipid uptake and triglyceride synthesis in the periphery, while stimulation of the CNS melanocortin system increased lipid mobilization in WAT [74]. Interestingly, the pharmacological data obtained from animal models might be of clinical relevance because obese patients deficient in MC4R showed an increased respiratory quotient, implicating melanocortin signaling in the regulation of substrate utilization in humans. With all this data, it is reasonable to hypothesize that impaired central control of nutrient partitioning, lipid deposition and lipid mobilization may contribute to the obesity phenotype in human MC4R deficiency.

Although the physiological effects of the central melanocortin system on fat metabolism are well established, little is known about the molecular pathways mediating...
these actions. A potential candidate for mediating these functions is the sympathetic nervous system because MC4R is located in its efferent neurons that innervate inguinal WAT [73]. This hypothesis was confirmed in a recent report using mice with a complete disruption of β-adrenergic signaling. When the central melanocortin system was altered in those mice, fat metabolism was unchanged – contrary to the effects observed in wild-type mice [74]. These genetic data were confirmed with electrophysiological studies showing that central stimulation of the CNS melanocortin system increases SNA in WAT, whereas central blockade of CNS melanocortin system has opposite actions [74].

In addition to its actions on WAT, the central melanocortin system also modulates hepatic lipid metabolism. Animals deficient in MC4R show an increased lipogenesis rate and triglyceride content in the liver [77]. Consistently, central administration of MC3/4R agonists reduced hepatic lipogenic gene expression [78], whereas the treatment with MC3/4R antagonists increased hepatic lipogenesis through the stimulation of SREBP-1c and PPAR-γ2 [79]. Finally, another issue regarding the central role of melanocortins is their function as an important regulator of cholesterol in rodents. This is an important point because the major plasma lipid abnormality in obesity is elevated triglycerides in the form of very low-density lipoproteins and low high-density lipoprotein cholesterol. The pharmacological or genetic inhibition of the brain's melanocortin system increases circulating high-density lipoprotein cholesterol by reducing its uptake by the liver independent of food intake or body weight [70]. In this sense, other neuropeptides have also been related to cholesterol metabolism. For instance, when the NPY is centrally administered in rodents, the secretion of triglycerides and, more specifically, very low-density lipoproteins are increased [80].

**Conclusions**

The hypothalamus is well known as a crucial regulator of both energy intake and energy expenditure. Studies carried out by different groups over the last years have uncovered novel molecular mechanisms involved in leptin and ghrelin action. One of those pathways involves AMPK-driven changes in hypothalamic lipid metabolism that subsequently influence neuropeptide gene expression. The CNS has also emerged as a relevant regulator of nutrient partitioning, changing the levels of adiposity independent of food intake. The fact that the CNS plays a key role in mediating feeding behavior, energy expenditure and nutrient partitioning reinforces the hypothesis that signals in the CNS are likely the most powerful pathways influencing energy balance. Indeed, these findings describe how endogenous hormones regulate (1) appetite through the AMPK-hypothalamic fatty acid metabolism and (2) peripheral adiposity through the sympathetic nervous system, and open new and exciting pathways for the discovery of a potential candidate drug target to fight obesity.

**Future Directions**

Several anatomical, pharmacological, genetic and physiological studies have demonstrated that specific hypothalamic neuronal populations regulate peripheral lipid metabolism. Although this brief review is focused on leptin, ghrelin and melanocortins, many other signals including glucagon-like peptide 1, resistin, insulin and NPY are also involved in the brain-adipose tissue cross-talk [11]. All these metabolic signals interact between them, making their molecular pathways complex and redundant. This might be the case for leptin and ghrelin, which signal through the same hypothalamic neuronal populations to trigger their biological actions. However, those two signals balance each other by having opposite actions [81, 82].

There are still some remaining issues that need to be addressed. For example, it is well established that leptin decreases NPY/AgRP expression and activates POMC activity, thereby leading to diminished feeding behavior, whereas ghrelin exerts opposite actions causing increased appetite. However, it is not fully clarified if the central actions of leptin and ghrelin controlling peripheral metabolism are mediated by these neuronal networks. Further studies assessing the metabolic actions of leptin and ghrelin in rodents with disrupted NPY/AgRP or POMC neuronal populations will help to understand if both hormones share common hypothalamic neural circuits to control food intake and peripheral metabolism.

Similar questions may be applied for the specific hypothalamic nuclei involved in mediating their actions. For example, it is clear that leptin requires the arcuate, ventromedial and paraventricular nuclei for decreasing feeding behavior, but the neurons commanding its peripheral actions are still poorly understood. Therefore, even though during the last years we have started to learn how the CNS controls hypothalamic and peripheral metabolism, there are some black boxes that need further
attention. Similarly, there is a general lack of knowledge on how different diets, gender and/or ageing influence the central control of peripheral lipid metabolism. Studies addressing the consequences of disruption of these central mechanisms on endpoints such as fat mass, liver steatosis and circulating levels of different biomarkers linked to cardiovascular risk are clearly needed. The precise knowledge of the metabolic brain-periphery cross-talk might allow for the development of drug targets for the treatment of obesity and its associated comorbidities.

Acknowledgements

This work has been supported by grants from Fondo Investigaciones Sanitarias (M.L.: PS09/01880), Ministerio de Ciencia e Innovación (C.D.: BFU2008-02001; M.L.: RyC-2007-00211; R.N.: RyC-2008-02219 and SAF2009-07049), Xunta de Galicia (M.L.: 10PXIB208164PR; R.N.: 2010/14) and the European Union (C.D., M.L. and R.N.: Health-Neurofast). CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII.

References


Hypothalamic Control of Lipid Metabolism

Neuroendocrinology 2011;94:1–11


